The Effect of Furosemide on Protein-Bound Uremic Toxin Plasma Levels and Excretion in Patients with Chronic Kidney Disease

• Conditions: Chronic Kidney Disease; reduced kidney function; 10038430

• Registration Number: NL-OMON56204
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 34

Inclusion Criteria

• An age of 18 years or older
• An eGFR <60 mL/min/1.73m2 for at least three months (diagnosis of CKD stage
3-5)
• An indication for the start of treatment with furosemide as part of routine
patient care
• Willingness to participate in the study and a signed informed consent

Exclusion Criteria

• Patients who are already on furosemide treatment
• Patients with a liver disease with hyperbilirubinemia
• Patients who receive any type of renal replacement therapy (peritoneal
dialysis, haemodialysis)
• Patients with end-stage renal failure without residual diuresis
• Patients who will start with medication simultaneously with start of
furosemide treatment that might interfere with PBUT excretion or PBUT protein
binding
• Patients who are incapacitated

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main endpoints of this study are PBUT plasma levels (indoxyl sulphate,<br /><br>p-cresyl sulphate, indole-3-acetic acid, kynurenic acid, L-kynurenine, hippuric<br /><br>acid en p-cresyl glucuronide) pre- and post-furosemide treatment </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Fractional PBUT excretion pre- and post-furosemide administration<br /><br>- Surrogate PBUT clearance pre- and post-furosemide administration<br /><br>- PBUT protein binding pre- and post-furosemide administration.</p><br>